Silo Pharma Shares Are Trading Lower. The Company Announced Results From a Preclinical Study on SPC-15.

BenzingaNov 18 13:07 ET

Silo Pharma, Inc. Announces Promising Preclinical Results for Dual-action Treatment SPC-15 Targeting PTSD and Severe Stress-related Conditions

Quiver QuantitativeNov 18 08:50 ET

Silo Pharma Announces Results From Preclinical Study On SPC-15, Highlighting Proposed Efficacy Of Combining SPC-15 With An NMDAR Antagonist

BenzingaNov 18 08:42 ET

Express News | Silo Pharma Inc - Combination Therapy Reduces Stress Behaviors in Animal Models

ReutersNov 18 08:40 ET

Express News | Silo Pharma Inc - Spc-15 Shows Potential for Treating Major Depressive Disorder

ReutersNov 18 08:40 ET

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

GlobeNewswireNov 18 08:40 ET